<DOC>
	<DOCNO>NCT01667263</DOCNO>
	<brief_summary>Randomized , open-label , multicentre study compare efficacy safety ATRA plus danazol danazol monotherapy patient corticosteroid-resistant/relapsed ITP .</brief_summary>
	<brief_title>The Combination ATRA Danazol Second-line Treatment Adult Immune Thrombocytopenia</brief_title>
	<detailed_description>Immune thrombocytopenia ( ITP ) severe bleed disorder . Approximately 2/3 patient achieve remission first-line therapy . However , underlie mechanism corticosteroid-resistant relapse ITP well understood ; thus , treatment remain great challenge . All-trans retinoic acid ( ATRA ) immunomodulatory effect haematopoiesis , make possible treatment option . A multicentre prospective study perform non-splenectomized ITP patient either resistant standard dose corticosteroid relapse . Patients randomize ATRA+danazol danazol monotherapy group . Platelet count , bleed symptom evaluate treatment . Adverse event also record throughout study , order compare efficacy safety ATRA plus danazol danazol monotherapy patient corticosteroid-resistant/relapsed ITP .</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<mesh_term>Danazol</mesh_term>
	<criteria>Primary immune thrombocytopenia ( ITP ) confirm exclude supervene cause thrombocytopenia ; Platelet count le 30×109/L enrolment Patients achieve sustain response treatment fulldose corticosteroid minimum duration 4 week relapse steroidtapering discontinuation . 18 year old . Secondary immune thrombocytopenia ( e.g. , patient HIV , HCV , Helicobacter pylori infection patient systemic lupus erythematosus ) congestive heart failure severe arrhythmia nursing pregnant woman aspartate aminotransferase alanine transaminase level ≥ 3× upper limit normal threshold criterion creatinine serum bilirubin level 1•5 time normal range active previous malignancy Unable blood routine test sake time , distance , economic issue reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>all-trans retinoid acid</keyword>
	<keyword>primary immune thrombocytopenia</keyword>
	<keyword>corticosteroid-resistant</keyword>
	<keyword>refractory</keyword>
	<keyword>danazol</keyword>
</DOC>